Drugs / Bifidobacterium infantis
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06793514 | Feb → May 2025 overdue | dry eye syndrome | Mohsen Pourazizi | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05687409 | Nov 2019 → May 2021 | cirrhosis of liver, metagonimiasis | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03644966 | Jul 2018 → Dec 2022 | bacterial infectious disease, urinary tract infection | Ochsner Health System | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01340469 Comparator | Jan 2005 → Mar 2008 | necrotizing enterocolitis, nosocomial infection | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01641341 Comparator | Nov 2010 → Mar 2012 | irritable bowel syndrome | American Academy of Family Physicians | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium infantis | “The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium...” NCT06793514 ↗3“Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.” NCT01340469 ↗ “Dietary Supplement: Bifidobacterium infantis” NCT03644966 ↗ |
| Known as | Bifidobacterium longum infantis | “A 10-g packet of lactulose oral solution and three capsules of probiotics (each containing \> 4.2×106 CFU Clostridium butyricum and \> 4.2×105 CFU Bifidobacterium longum infantis).” NCT05687409 ↗ |
| Modality | Other / unclassified | “live Lactobacillus acidophilus and Bifidobacterium infantis” NCT01340469 ↗ |
| Route | Other | “Daily enteral probiotic supplementation” NCT01340469 ↗ |